:::
Kuan-Ying Arthur Huang

Kuan-Ying Arthur Huang

Education and Experience

  • 2011  Ph.D.  Nuffield Department of Clinical Medicine, University of Oxford, UK
  • 2002   B.S.    School of Medicine, National Taiwan University

Experience

  • 2022-           Associate Professor, Graduate Institute of Immunology, National Taiwan University
  • 2022-           Attending Physician, Department of Pediatrics, National Taiwan University Hospital
  • 2022-2022  Professor, Chang Gung University
  • 2021-2022   Professor, Chang Gung Medical Foundation
  • 2018-2022   Associate Professor, Chang Gung University
  • 2016-2021   Associate Professor, Chang Gung Medical Foundation
  • 2012-2016   Assistant Professor, Chang Gung Medical Foundation

Awards and Honors

  • 2022   Outstanding Paper Award, Infectious Diseases Society of Taiwan
  • 2021   Young Investigator Award, TienTe Lee Biomedical Foundation
  • 2021   Outstanding Junior Investigator Program, Ministry of Science and Technology
  • 2020   Outstanding Junior Investigator Program, Ministry of Science and Technology
  • 2019    Poster Award in first place, Infectious Diseases Society of Taiwan
  • 2019    Outstanding Paper Award, Infectious Diseases Society of Taiwan
  • 2017    Outstanding Research Paper Award for Attending physician, Chiung-Lin Chen Pediatric Research Award Foundation
  • 2014   Best Research Award, Pediatric Academic Societies and Asian Society for Pediatric Research
  • 2008   Outstanding Research Paper Award for Resident in first place, Infectious Diseases Society of Taiwan

Research Interests and Directions

  1. Chen CJ et al. A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19. Nature Communications 2022;13:5466.
  2. Chen CP et al. Anti-Spike Antibody Response to Natural Infection with SARS-CoV-2 and Its Activity against Emerging Variants. Microbiology Spectrum 2022;10:e0074322.
  3. Huang KA et al. Structures and therapeutic potential of anti-RBD human monoclonal antibodies against SARS-CoV-2. Theranostics 2022;12:1-17.
  4. Huang KA*. Structural basis for neutralization of enterovirus. Current Opinion in Virology 2021;51:199-206.
  5. Huang KA et al. Breadth and function of antibody response to acute SARS-CoV-2 infection in humans. PLoS Pathogens 2021;17:e1009352.
  6. Huang KA et al. Structural and functional analysis of protective antibodies targeting the threefold plateau of enterovirus 71. Nature Communications 2020;11:5253.
  7. Huang KA et al. Emergence of genotype C1 Enterovirus A71 and its link with antigenic variation of virus in Taiwan. PLoS Pathogens 2020;16:e1008857.
  8. Zhou D et al. Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient. Nature Structural & Molecular Biology 2020;27:950-958.
  9. Rijal P et al. Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans. Journal of Virology 2020;94:e01182-19.
  10. Huang KA et al. Structure-function analysis of neutralizing antibodies to H7N9 influenza from naturally infected humans. Nature Microbiology 2019;4:306-315.
  11. Huang KA et al. Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nature Communications 2017;8:762.
  12. Huang KA et al. A Potent Virus-Specific Antibody-Secreting Cell Response to Acute Enterovirus 71 Infection in Children. Journal of Infectious Diseases 2015;212:808-17.
  13. Huang KA et al. Focused antibody response to influenza linked to antigenic drift. Journal of Clinical Investigation 2015;125:2631-45.